NADMED Innovates with Advanced NAD Testing Technology

Thursday, 22 August 2024, 01:38

Finnish biotech firm NADMED successfully raises €3.5M in a Series A round, aiming to revolutionize how we measure NAD levels using fresh blood samples. This groundbreaking technology ensures enhanced accuracy by utilizing mass spectrometry-level precision. The funding will propel NADMED’s efforts to bring this innovative testing method to the forefront of biotechnology.

Siliconcanals — NADMED Innovates with Advanced NAD Testing Technology

Finnish biotech firm NADMED has successfully raised €3.5 million in a Series A funding round.

This funding will support NADMED’s groundbreaking approach to efficiently measuring all four NAD levels using fresh blood samples.

By leveraging mass spectrometry-level accuracy, their testing method signals a significant advancement in biotechnology.

Investors are optimistic about the potential for NADMED to lead in this niche market.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts